<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209592">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359190</url>
  </required_header>
  <id_info>
    <org_study_id>EGF10027</org_study_id>
    <nct_id>NCT00359190</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer</brief_title>
  <official_title>A Phase I, Open Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Versus Twice Daily Dosing Regimens in Patients With Treatment- Naive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the inhibition of ErbB1 and ErbB2 phosphorylation and downstream
      mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer
      patients for three dosing schedules of lapatinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the effects of 3 dosing schedules of lapatinib on biomarkers involved in regulating tumor cell proliferation and survival in pre-treatment and post-treatment breast tumor tissue samples.</measure>
    <time_frame>subjects on study up to 15 days</time_frame>
    <description>biomarker analysis of tumor biopsies pre/post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of adverse events and changes in lab values from pre-dose and post-dose. Assessment of safety &amp; tolerability of lapatinib at multiple doses when administered to patients who have not have not been treated for breast tumors.</measure>
    <time_frame>subjects on study up to 15 days</time_frame>
    <description>safety assessments of labs, hematology labs, Electrocardiogram, vital signs</description>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Neoplasms, Breast</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Clinical labs are within acceptable ranges.

          -  A histologically confirmed, treatment-naive, breast tumor measuring 1 cm or greater
             that can be readily biopsied.

          -  At least 18 years of age.

          -  Females must meet certain criteria specified in protocol.

          -  Ability to swallow and retain oral medication.

          -  Ability to follow and understand directions.

        Exclusion criteria:

          -  Female who is pregnant or lactating.

          -  Medically unfit by the doctor as a result of the medical interview or physicals.

          -  Received treatment of an investigational drug within 4 weeks of study start.

          -  Currently receiving treatment with prohibited meds listed in protocol.

          -  Had major surgery in previous 2 weeks.

          -  Had prior radiation therapy to the chest to treat this incidence of breast cancer.

          -  Hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study
             med.

          -  Has a malabsorption syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 14, 2016</lastchanged_date>
  <firstreceived_date>July 28, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lapatinib</keyword>
  <keyword>breast cancer</keyword>
  <keyword>treatment-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
